Literature DB >> 7965676

Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine.

T G Burke1, X Gao.   

Abstract

Topotecan is a promising anticancer agent presently undergoing clinical evaluation worldwide. Topotecan, camptothecin, 9-aminocamptothecin, and CPT-11 have aroused considerable interest in recent years for their ability to halt the growth of a wide range of human tumors. For each analogue an important structural requirement for biological activity is a closed alpha-hydroxy lactone ring moiety. Unfortunately, this functionality hydrolyses rapidly in aqueous solution under physiological conditions (i.e. pH 7 or above), resulting in an inactive carboxylate form of the drug. In this report, we demonstrate that topotecan's half-life in human plasma (pH 7.6) can be enhanced dramatically by packaging the drug within the aqueous, pH 5-adjusted confines of lipid vesicles composed of diasteroylphosphatidylcholine. We have also demonstrated that drug sequestration within the liposomal particles can be efficiently accomplished. Thus, our preliminary experiments suggest that liposomes may be of potential utility for markedly improving the stability of topotecan in circulation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7965676     DOI: 10.1002/jps.2600830710

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

Review 1.  Camptothecin delivery methods.

Authors:  A Hatefi; B Amsden
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

2.  Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts.

Authors:  Laura P Serwer; Charles O Noble; Karine Michaud; Daryl C Drummond; Dmitri B Kirpotin; Tomoko Ozawa; Michael D Prados; John W Park; C David James
Journal:  Neuro Oncol       Date:  2011-09-27       Impact factor: 12.300

3.  Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.

Authors:  Ryuta Saito; Michal T Krauze; Charles O Noble; Daryl C Drummond; Dmitri B Kirpotin; Mitchel S Berger; John W Park; Krystof S Bankiewicz
Journal:  Neuro Oncol       Date:  2006-05-24       Impact factor: 12.300

4.  A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies.

Authors:  John F Deeken; Rebecca Slack; Glen J Weiss; Ramesh K Ramanathan; Michael J Pishvaian; Jimmy Hwang; Karen Lewandowski; Deepa Subramaniam; Aiwu Ruth He; Ion Cotarla; Aquilur Rahman; John L Marshall
Journal:  Cancer Chemother Pharmacol       Date:  2012-12-30       Impact factor: 3.333

5.  Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer.

Authors:  Nilesh A Patankar; Dawn Waterhouse; Dita Strutt; Malathi Anantha; Marcel B Bally
Journal:  Invest New Drugs       Date:  2012-05-22       Impact factor: 3.850

6.  Insights into accelerated liposomal release of topotecan in plasma monitored by a non-invasive fluorescence spectroscopic method.

Authors:  Kyle D Fugit; Amar Jyoti; Meenakshi Upreti; Bradley D Anderson
Journal:  J Control Release       Date:  2014-10-25       Impact factor: 9.776

7.  Stabilization of 10-hydroxycamptothecin in poly(lactide-co-glycolide) microsphere delivery vehicles.

Authors:  A Shenderova; T G Burke; S P Schwendeman
Journal:  Pharm Res       Date:  1997-10       Impact factor: 4.200

Review 8.  Liposomal drug formulations. Rationale for development and what we can expect for the future.

Authors:  T M Allen
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.